These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 23682851)

  • 21. Everolimus leads to a lower risk of BKV viremia than mycophenolic acid in de novo renal transplantation patients: a single-center experience.
    Moscarelli L; Caroti L; Antognoli G; Zanazzi M; Di Maria L; Carta P; Minetti E
    Clin Transplant; 2013; 27(4):546-54. PubMed ID: 23758330
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sirolimus versus calcineurin inhibitor-based immunosuppressive therapy in kidney transplantation: a 4-year follow-up.
    Nafar M; Alipour B; Ahmadpoor P; Pour-Reza-Gholi F; Samadian F; Samavat S; Farhangi S
    Iran J Kidney Dis; 2012 Jul; 6(4):300-6. PubMed ID: 22797101
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proteinuria and sirolimus after renal transplantation: a retrospective analysis from a large German multicenter database.
    Naik MG; Heller KM; Arns W; Budde K; Diekmann F; Eitner F; Fischereder M; Goßmann J; Heyne N; Morath C; Riester U; Gwinner W; Jürgensen JS;
    Clin Transplant; 2014 Jan; 28(1):67-79. PubMed ID: 24372584
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
    Uslu A; Nart A; Taşli FA; Postaci H; Aykas A; Doğan M; Sahin T
    Nephrology (Carlton); 2008 Feb; 13(1):80-6. PubMed ID: 18199109
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association between elevated whole blood Epstein-Barr virus (EBV)-encoded RNA EBV polymerase chain reaction and reduced incidence of acute lung allograft rejection.
    Ahya VN; Douglas LP; Andreadis C; Arnoldi S; Svoboda J; Kotloff RM; Hadjiliadis D; Sager JS; Woo YJ; Pochettino A; Schuster SJ; Stadtmauer EA; Tsai DE
    J Heart Lung Transplant; 2007 Aug; 26(8):839-44. PubMed ID: 17692789
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Conversion to sirolimus in kidney transplant recipients: a single-center study.
    Ganji MR; Hakemi MS; Esfehani F; Alatab S; Naderi GH
    Iran J Kidney Dis; 2013 Jul; 7(4):309-15. PubMed ID: 23880809
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multifocal histologically malignant Epstein-Barr virus-associated smooth muscle tumor in a pediatric transplant patient with an indolent course.
    Kazmi SA; Aizenberg MR; Harper JL; McComb RD
    Int J Surg Pathol; 2014 Apr; 22(2):186-9. PubMed ID: 23842005
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epstein-Barr virus-associated smooth muscle tumors are distinctive mesenchymal tumors reflecting multiple infection events: a clinicopathologic and molecular analysis of 29 tumors from 19 patients.
    Deyrup AT; Lee VK; Hill CE; Cheuk W; Toh HC; Kesavan S; Chan EW; Weiss SW
    Am J Surg Pathol; 2006 Jan; 30(1):75-82. PubMed ID: 16330945
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cyclosporine versus everolimus: effects on the glomerulus.
    Baas MC; Kers J; Florquin S; de Fijter JW; van der Heide JJ; van den Bergh Weerman MA; ten Berge IJ; Bemelman FJ
    Clin Transplant; 2013; 27(4):535-40. PubMed ID: 23795805
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful medical treatment of EBV smooth muscle tumor in a renal transplant recipient.
    Belingheri M; Comoli P; Locatelli F; Baldanti F; Martina V; Giani M; Ferraresso M; Cro L; Edefonti A; Ghio L
    Pediatr Transplant; 2010 Dec; 14(8):E101-4. PubMed ID: 19659510
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
    Sundberg AK; Rohr MS; Hartmann EL; Adams PL; Stratta RJ
    Clin Transplant; 2004; 18 Suppl 12():61-6. PubMed ID: 15217410
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment.
    Muti G; Cantoni S; Oreste P; Klersy C; Gini G; Rossi V; D'Avanzo G; Comoli P; Baldanti F; Montillo M; Nosari A; Morra E;
    Haematologica; 2002 Jan; 87(1):67-77. PubMed ID: 11801467
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized, open-label study of sirolimus versus cyclosporine in primary de novo renal allograft recipients.
    Flechner SM; Gurkan A; Hartmann A; Legendre CM; Russ GR; Campistol JM; Schena FP; Hahn CM; Li H; Korth-Bradley JM; Tai SS; Schulman SL
    Transplantation; 2013 May; 95(10):1233-41. PubMed ID: 23689085
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Posttransplant Epstein-Barr virus-associated myogenic tumors: case report and review of the literature.
    Sprangers B; Smets S; Sagaert X; Wozniak A; Wollants E; Van Ranst M; Debiec-Rychter M; Sciot R; Vanrenterghem Y; Kuypers DR
    Am J Transplant; 2008 Jan; 8(1):253-8. PubMed ID: 18184312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
    Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epstein-Barr viral infection in renal allograft recipients: a single center experience.
    Zadeh ZR; Makhdumi K; Lak SS
    Saudi J Kidney Dis Transpl; 2006 Sep; 17(3):351-4. PubMed ID: 16970255
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epstein-Barr virus-associated smooth muscle tumours after transplantation, infection with human immunodeficiency virus and congenital immunodeficiency syndromes.
    Hussein K; Maecker-Kolhoff B; Donnerstag F; Laenger F; Kreipe H; Jonigk D
    Pathobiology; 2013; 80(6):297-301. PubMed ID: 24013109
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of Epstein-Barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients.
    Sampaio MS; Cho YW; Shah T; Bunnapradist S; Hutchinson IV
    Nephrol Dial Transplant; 2012 Jul; 27(7):2971-9. PubMed ID: 22273720
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies.
    Larsen CP; Grinyó J; Medina-Pestana J; Vanrenterghem Y; Vincenti F; Breshahan B; Campistol JM; Florman S; Rial Mdel C; Kamar N; Block A; Di Russo G; Lin CS; Garg P; Charpentier B
    Transplantation; 2010 Dec; 90(12):1528-35. PubMed ID: 21076381
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.